PATENT CLAIM ANALYSIS

Application Number: 15939218
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-08
Patent Classification: ["514", "428000"]

Abstract:
The disclosure provides methods for treating estrogen receptor positive (ER + ) cancer in women with an effective amount of lasofoxifene, a pharmaceutically acceptable salt thereof, or a prodrug thereof. The disclosure also includes the detection of the Estrogen Receptor 1 (ESR1) gene mutations that lead to endocrine resistance and treatment of endocrine resistant ER +  cancers.

Claim (Index 4):
The method of  claim 1 , wherein the at least one of gain of function missense mutation is in any one of amino acids D538, Y537, L536, P535, V534, S463, V392, and E380 of the ER\u03b1 protein.

Metadata:
- Claim Count in Document: 65.0
- Percentile: 90.0
- Lexical Diversity: 1.28
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14645578', '14753397', '14717069', '15589391', '16475980']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7934646225352048
- 35 USC 102 Novelty (BERT): 0.5235125549119612
- Combined Prediction Score: 0.7664694157728804
- Mean Citation Score: 320.457534
- Max Citation Score: 345.9269700000001
- Similarity Product: 278.7660010822607

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test